Edgewise Therapeutics, Inc. (EWTX) Stock Forecast
EWTX analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.46 / 5 from 13 analysts
- Price target
- $52.62 average of analyst targets
- Upside to target
- +41.5% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.55
- 52-week range
- $14.89 – $48.35
EWTX analyst ratings
13 analystsNumber of analysts at each rating.
EWTX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
EWTX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $2.51 | −$0.64 | $11.45 | −$0.39 | +744.4% | 11 |
| Current fiscal year (2026) | $2.27 | −$2.42 | $11.22 | −$1.63 | +239.6% | 11 |
| Next fiscal year (2027) | −$1.77 | −$3.44 | −$0.47 | $2.27 | −178.0% | 12 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
EWTX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $119.2M | $0 | $1.55B | 0.0% | 13 |
| Current fiscal year (2026) | $128.8M | $0 | $1.68B | 0.0% | 13 |
| Next fiscal year (2027) | $39.2M | $0 | $200.0M | −69.6% | 12 |
EWTX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
EWTX revenue: reported and forecast
EWTX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.13 | $2.81 | $2.81 | $2.81 | $2.51 | +121.8% | 1 up · 4 down |
| Current fiscal year (2026) | −$0.23 | $1.39 | $1.38 | $1.38 | $2.27 | −1,070.9% | 0 up · 5 down |
| Next fiscal year (2027) | −$1.47 | −$1.78 | −$1.82 | −$1.82 | −$1.77 | +20.4% | 1 up · 6 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
EWTX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; EWTX beat in 7 of 12.
What analysts expect from EWTX
13 analysts cover Edgewise Therapeutics; their consensus rating is buy (4.46 on a 1–5 scale, where 5 is a strong buy). The average price target is $52.62, 41.5% above the latest close of $37.19. Analysts expect earnings of $2.27 per share for 2026, +239.6% from a year earlier. For 2027 the average estimate is −$1.77 per share on revenue of $39.2 million. Edgewise Therapeutics beat the EPS estimate in 7 of the last 12 quarters.
Related: EWTX income statement, EWTX key metrics, EWTX chart. See the EWTX stock overview for the latest quote and news.
EWTX forecast FAQ
What is Edgewise Therapeutics's price target?
The average analyst price target for Edgewise Therapeutics is $52.62, 41.5% above the latest close of $37.19.
Is Edgewise Therapeutics a buy, hold or sell?
Of 13 analysts covering Edgewise Therapeutics, 8 rate it a strong buy, 3 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Edgewise Therapeutics's EPS forecast?
Analysts forecast $2.27 per share for 2026 (range −$2.42 to $11.22); for 2027 the estimate is −$1.77.
What is Edgewise Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $128.8 million, growth of 0.0%; for 2027 it is $39.2 million.
When does Edgewise Therapeutics report earnings?
Edgewise Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens; the EPS estimate is $-0.55.
Does Edgewise Therapeutics usually beat earnings estimates?
Edgewise Therapeutics reported EPS at or above the analyst estimate in 7 of the last 12 quarters.